RxDoctor Payments Data

Harminder Sandhu, MD

Nephrology · Washington, DCNPI 1992966931

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,251 of the $2,890 with a category attached, or 77.9%. It is spread thinly across 18 manufacturers, the largest accounting for just 22.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $679 and has fallen 64.3% since, to $242 in 2025.

$2,890in general payments, 2019–2025

Across 45 payments — averaging $64.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merit Medical Systems Inc$639
  • AstraZeneca$561
  • Ardelyx, Inc.$380
  • Fresenius USA Marketing, Inc.$207
  • Bard Peripheral Vascular, Inc.$164
  • Bayer$163
  • plus $775 from 12 others

What the payments were for

  • Travel & lodging$63922%
  • Food & beverage$2,25178%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,890 in reported general payments places this provider in the 75th percentile of 62 nephrology providers in District of Columbia.

See all nephrology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$313,008
Medicare patients
430
Services billed
3,375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JulucaDolutegravir/Rilpivirine11$38,612
Sevelamer Carbonate19$1,262
Calcitriol23$579
Midodrine Hcl23$532
Levothyroxine Sodium13$139
Mirtazapine11$112
Furosemide18$92
Hydralazine Hcl17$59
Tamsulosin Hcl12$53
Losartan Potassium13$52
Citalopram HbrCitalopram Hydrobromide11$20

Paid to pharmacies, not to this prescriber.

Other nephrology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →